Humacyte Approves Key Proposals at Annual Meeting

Humacyte ( (HUMA) ) has shared an announcement.

On June 10, 2025, Humacyte held its Annual Meeting where stockholders voted on three key proposals. The election of four Class I directors was confirmed, PricewaterhouseCoopers LLP was ratified as the independent auditor for the fiscal year ending December 31, 2025, and an amendment to increase the number of authorized shares of common stock from 250 million to 350 million was approved.

The most recent analyst rating on (HUMA) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Humacyte stock, see the HUMA Stock Forecast page.

Spark’s Take on HUMA Stock

According to Spark, TipRanks’ AI Analyst, HUMA is a Neutral.

Humacyte’s overall stock score reflects significant financial and technical challenges. The lack of revenue, persistent losses, and negative equity weigh heavily on the financial performance. Technical analysis indicates bearish momentum. The valuation metrics suggest the stock may be overpriced given the negative P/E ratio and absence of dividends. The earnings call offered some optimism regarding future growth due to FDA approvals and product launches, but these are long-term prospects amid current financial difficulties. Recent corporate events provide mixed signals with potential legal risks and a successful capital raise.

To see Spark’s full report on HUMA stock, click here.

More about Humacyte

Average Trading Volume: 4,890,872

Technical Sentiment Signal: Sell

Current Market Cap: $414.2M

Learn more about HUMA stock on TipRanks’ Stock Analysis page.